Patient Zero: A Joe Ledger Novel
Encyclopedia
Patient Zero by Jonathan Maberry
is a bioterrorism
thriller about a bioweapon that turns humans into zombies. It was published in 2009, and is the first of the Joe Ledger series.
protein. DMS is very short-handed because "bravo" team and "charlie" Team were wiped out in an outbreak at a hospital, and the protagonist, Joe Ledger, is installed as the head of the new "Echo" Team. Meanwhile, a Middle East terrorist group led by El Mujahid is developing new, faster-acting strains of the disease. The funding for the new strains is coming from a pharmaceutical company called Gen2000.
Jonathan Maberry
Jonathan Maberry is the multiple Bram Stoker Award-winning author of Ghost Road Blues, the first of the Pine Deep Trilogy, a series of supernatural horror novels...
is a bioterrorism
Bioterrorism
Bioterrorism is terrorism involving the intentional release or dissemination of biological agents. These agents are bacteria, viruses, or toxins, and may be in a naturally occurring or a human-modified form. For the use of this method in warfare, see biological warfare.-Definition:According to the...
thriller about a bioweapon that turns humans into zombies. It was published in 2009, and is the first of the Joe Ledger series.
Plot summary
The story follows a Baltimore detective who is recruited into the Department of Military Sciences (DMS) and has to fight terrorists and flesh-eating zombies created by a pathogen called "Sword of the Faithful". Sword of the Faithful is a parasite that infects the brain with PrionPrion
A prion is an infectious agent composed of protein in a misfolded form. This is in contrast to all other known infectious agents which must contain nucleic acids . The word prion, coined in 1982 by Stanley B. Prusiner, is a portmanteau derived from the words protein and infection...
protein. DMS is very short-handed because "bravo" team and "charlie" Team were wiped out in an outbreak at a hospital, and the protagonist, Joe Ledger, is installed as the head of the new "Echo" Team. Meanwhile, a Middle East terrorist group led by El Mujahid is developing new, faster-acting strains of the disease. The funding for the new strains is coming from a pharmaceutical company called Gen2000.